UPDATE: Sterne Agee Reiterates Buy Rating, Raises PT on Allscripts Healthcare Solutions
In a report published Monday, Sterne Agee Group reiterated its Buy rating on Allscripts Healthcare Solutions (NASDAQ: MDRX), and raised its price target from $13.50 to $15.00.
Sterne Agee noted, “Our analysis suggests a $15-19 valuation range for MDRX shares should a go-private transaction be consummated by year-end. At the low end, this valuation range is 20% above today's closing price, while the top end implies 50% upside. As such, we have raised our price target to $15 per share from $13.50.”
Allscripts Healthcare Solutions closed on Friday at $12.42.
Latest Ratings for MDRX
|Jan 2017||Cantor Fitzgerald||Initiates Coverage On||Neutral|
|Dec 2016||Morgan Stanley||Downgrades||Overweight||Underweight|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.